# POINT Biopharma Global Inc. (PNT)

Source: https://www.quantisnow.com/company/PNT
Generated: 2026-11-10T07:26:38.526Z

- Ticker: PNT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- Website: pointbiopharma.com

## About

POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.

## Latest PNT news and filings

- 2024-05-28 13:30 UTC [Leadership Update] [Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors](https://www.quantisnow.com/insight/delcath-systems-announces-appointment-of-bridget-martell-ma-md-to-5519128)
- 2024-01-08 12:00 UTC [SEC Form 15-12G filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-point-biopharma-global-inc-5174552)
- 2024-01-03 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-point-biopharma-global-inc-5162634)
- 2024-01-03 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-point-biopharma-global-inc-5162633)
- 2023-12-27 22:41 UTC [SEC Form 4] [SEC Form 4 filed by Goodman Jonathan R.](https://www.quantisnow.com/insight/sec-form-4-filed-by-goodman-jonathan-r-5156578)
- 2023-12-27 22:40 UTC [SEC Form 4] [SEC Form 4 filed by Kelly Justyna](https://www.quantisnow.com/insight/sec-form-4-filed-by-kelly-justyna-5156577)
- 2023-12-27 22:40 UTC [SEC Form 4] [Mccann Joe A. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/mccann-joe-a-closing-all-direct-ownership-in-the-company-5156576)
- 2023-12-27 22:39 UTC [SEC Form 4] [SEC Form 4 filed by Jensen Jessica D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-jensen-jessica-d-5156574)
- 2023-12-27 22:39 UTC [SEC Form 4] [Fleshner Neil E. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/fleshner-neil-e-closing-all-direct-ownership-in-the-company-5156572)
- 2023-12-27 22:37 UTC [SEC Form 4] [Hogue Gerald L. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/hogue-gerald-l-closing-all-direct-ownership-in-the-company-5156570)
- 2023-12-27 22:37 UTC [SEC Form 4] [Malik Rajesh closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/malik-rajesh-closing-all-direct-ownership-in-the-company-sec-5156569)
- 2023-12-27 22:37 UTC [SEC Form 4] [Lubner David Charles returned 3,600 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/lubner-david-charles-returned-3600-shares-to-the-company-closing-5156568)
- 2023-12-27 22:36 UTC [SEC Form 4] [SEC Form 4 filed by Demers William L.](https://www.quantisnow.com/insight/sec-form-4-filed-by-demers-william-l-5156566)
- 2023-12-27 22:35 UTC [SEC Form 4] [SEC Form 4 filed by Silber Allan C](https://www.quantisnow.com/insight/sec-form-4-filed-by-silber-allan-c-5156563)
- 2023-12-27 22:35 UTC [SEC Form 4] [Margolin Yael returned 1,710 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/margolin-yael-returned-1710-shares-to-the-company-closing-all-5156562)
- 2023-12-27 22:02 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-point-biopharma-global-inc-5156469)
- 2023-12-27 17:42 UTC [Market Insight] [Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned](https://www.quantisnow.com/insight/recent-ma-bodes-well-for-targeted-cancer-therapy-player-fusion-5155991)
- 2023-12-27 14:44 UTC [SEC Form POS AM filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-point-biopharma-global-inc-5155780)
- 2023-12-27 14:43 UTC [SEC Form POS AM filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-point-biopharma-global-inc-5155778)
- 2023-12-27 14:42 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-point-biopharma-global-inc-5155777)
- 2023-12-27 14:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-point-biopharma-global-inc-5155776)
- 2023-12-27 14:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-point-biopharma-global-inc-5155773)
- 2023-12-27 14:26 UTC [SEC Form 25-NSE filed by POINT Biopharma Global Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-point-biopharma-global-inc-5155755)
- 2023-12-27 13:54 UTC [SEC Form 8-K] [POINT Biopharma Global Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/point-biopharma-global-inc-filed-sec-form-8-k-termination-of-5155681)
- 2023-12-27 13:31 UTC [Mergers & Acquisitions] [Lilly Completes Acquisition of POINT Biopharma](https://www.quantisnow.com/insight/lilly-completes-acquisition-of-point-biopharma-5155648)
- 2023-12-23 00:19 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-point-biopharma-global-inc-5154195)
- 2023-12-22 23:40 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-point-biopharma-global-inc-5154193)
- 2023-12-21 10:47 UTC [Market Chatter] [Brookline Capital Downgrades POINT Biopharma Global to Hold, Lowers Price Target to $12.5](https://www.quantisnow.com/insight/brookline-capital-downgrades-point-biopharma-global-to-hold-lowers-price-5149827)
- 2023-12-20 23:09 UTC [SEC Form 4] [Bvf Partners L P/Il sold $213,657,911 worth of shares (17,161,278 units at $12.45) (SEC Form 4)](https://www.quantisnow.com/insight/bvf-partners-l-pil-sold-213657911-worth-of-shares-17161278-5149653)
- 2023-12-20 21:38 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-point-biopharma-global-inc-5149327)
- 2023-12-20 13:05 UTC [Leadership Update] [Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors](https://www.quantisnow.com/insight/purple-biotech-appoints-dr-yael-margolin-to-its-board-of-5148042)
- 2023-12-19 19:52 UTC [Market Insight] [Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug](https://www.quantisnow.com/insight/lantheus-downgraded-due-to-reliance-on-pnt2002-analyst-cites-comparable-5146082)
- 2023-12-18 16:47 UTC [Market Insight] [Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?](https://www.quantisnow.com/insight/why-is-prostate-cancer-focused-lantheus-stock-trading-lower-today-5142960)
- 2023-12-18 16:33 UTC [Market Chatter] [POINT Biopharma shares are trading lower after the company and Lantheus announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.](https://www.quantisnow.com/insight/point-biopharma-shares-are-trading-lower-after-the-company-and-5142934)
- 2023-12-18 13:14 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-point-biopharma-global-inc-5142337)
- 2023-12-18 12:31 UTC [Market Chatter] [Lantheus and POINT Biopharma Announce Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/lantheus-and-point-biopharma-announce-topline-results-from-pivotal-splash-5142101)
- 2023-12-18 12:30 UTC [Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/lantheus-and-point-biopharma-announce-positive-topline-results-from-pivotal-5142089)
- 2023-12-18 11:59 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-point-biopharma-global-inc-5141989)
- 2023-12-18 11:45 UTC [Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023](https://www.quantisnow.com/insight/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-5141942)
- 2023-12-04 12:22 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by POINT Biopharma Global Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-point-biopharma-global-inc-5115148)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PNT
- Earnings history: https://www.quantisnow.com/earnings/PNT
- Dividend history: https://www.quantisnow.com/dividends/PNT
- Insider transactions: https://www.quantisnow.com/insiders/PNT
- Options chain: https://www.quantisnow.com/options/PNT
- SEC 8-K filings only: https://www.quantisnow.com/company/PNT/8-k
- RSS and alerts for PNT: https://www.quantisnow.com/docs/rss-feeds.md